Zoetis Services LLC

The University of Texas System

United States of America, as Represented by the Secretary of Agriculture

Iowa State University Research Foundation Inc

Pfizer Corporation

Pfizer Products Inc.

John Morgan Hardham

Paul Joseph Dominowski

Alan G Barbour

Steven J Norris

George M Weinstock

Jing-Ren Zhang

Jerrilyn K Howell

Duncan Mwangi

Sharath K Rai

Dennis L Foss

Richard Lee Krebs

Aida Elizabeth Rieder

Luis Leandro Rodriguez

Suman Mahan

Cyril Gay

Shaunak Vora

Sangita Mediratta

Peter William Krug

Kaori Mohr

Sarah A Salmon

Lauren Wilmes

Sandra Ann Marie Lightle

Guillermo Gallo

James Alan Jackson

Jay Gregory Calvert

James Richard Thompson

Jacqueline Gayle Marx

Qi Chen

Mira Ivanova Stoeva

Phillip Gauger

Jianqiang Zhang

Laia Plaja Dilmé

Oscar Romero Galindo

Alicia Urniza Hostench

Marta Cabana Sumsi

Monica Balasch Sanuy

Vicki Jon Rapp Gabrielson

Walter Valdez

Meggan Bandrick

Darin Madson

Kendall Wayne King

Rajendra Krishnan

Kimberly Jean Dreier

David Ross McGavin

Steven Alan Dunham

Mahesh Kumar

Eric Baima

John David Haworth

David George Emslie Smith

Jason John Millership

Anita Dorota Jaglarz

Sharon Marie Wappel

Yulia Burakova

Jemlyn K Howell

Nicole Lynn Hainer

Galindo Oscar Romero

Dilme Laia Plaja

Sanuy Monica Balasch

Hostench Alicia Urniza

Sumsi Marta Cabana

Cyril Gerard Gay

William Donachie

Michael Christopher Fontaine

Julie Lydia Fitzpatrick

Laia Plaja Dilme

The present invention is directed to novel nucleotide and amino acid sequences of Porcine Epidemic Diarrhea Virus ('PEDV'), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PEDV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length PEDV genomes that can replicate efficiently in host animals and tissue culture.

Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom

The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The present invention is also directed to novel immunogenic compositions that protect swine from disease caused by porcine deltacoronavirus (PDCoV), alone or as combination vaccine to protect against PEDV. The compositions of the invention provide killed viruses whose effectiveness is enhanced by the selection of preferred adjuvants. Novel culture methods are also employed to increase reproducible yield of cultured viruses. Live vaccines are also provided from the Calaf14 PEDV isolate.

Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus

The invention provides stable coronavirus spike proteins. Immunogenic compositions comprising same and the methods of using these immunogenic compositions are also provided.

Anti-coronavirus vaccines

Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 μg FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.

Foot-and-mouth disease vaccine

The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.

Oil-based adjuvants

Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 &#x3bc;g FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.

Compositions for prevention of Foot and Mouth Disease (FM D) are provided, comprising an antigen component in the amount equivalent to 0.5-20 &#x3bc;g FM D virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FM D persistence are also provided.

Growing community of inventors

Gales Ferry, CT, United States of America

John Morgan Hardham